Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say - Reuters

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPbmV4NWgtNHIxcFNOYk8tdEdrZVQ2cmdKQUJsWG12bUszbXVLN3NJZWo1VnowM0NocTVPb3RtQ2dSWE5JeXJiRnF4RkR4LVlGcEtrZHRTWUxnS3UyajM3QUlUbDVhZ0pqZWdCSE5QRS1QTE9BekIyTlF2OFZqZFF0SHZCaHZVTHZ3amRfd3VUdGZUSUlsQm9jZDg5M3FHaDBDdGFkc1hFM0t3U1N6SkxvamppdUMyVmFicHA0VDZDSQ?oc=5" target="_blank">Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Inhibrx Biosciences is exploring a joint spin-off of its experimental cancer drug, INBRX-106, which is being tested alone and in combination with Merck's Keytruda. The potential valuation of the drug could exceed $8 billion if clinical trials confirm its efficacy.

Merck & Co, Germany's Merck KGaA, and Japan's Ono Pharmaceutical are reportedly interested in Inhibrx's experimental cancer treatment, INBRX-106, which is being tested alone and in combination with Merck's Keytruda. The drug could be valued at over $8 billion if clinical trials are successful.